CommercialCoverageMedium impact
Spevigo ® (Spesolimab-Sbzo)
UnitedHealthcare·Dermatology·Medical Benefit Drug Policy
Effective date
Jun 1, 2026
We identified it
Jun 2, 2026
Summary
UHC has updated their medical benefit drug policy for Spevigo (Spesolimab-Sbzo), a specialty medication used for treating generalized pustular psoriasis. This policy update affects coverage criteria, prior authorization requirements, or administration guidelines for this high-cost specialty drug.
Action Required
By June 1, 2026: Billing team must review updated Spevigo coverage criteria and prior authorization requirements. Update billing system with new policy guidelines for Spesolimab-Sbzo claims. Notify dermatology providers of any changes to administration or documentation requirements. Verify current prior auth processes align with updated policy to prevent claim denials.